Family Medicine | Page 121 of 374 | Links Medicus Content Curation & Alerts in Medicine

RCT: One-time flexible sigmoidoscopy screening is associated with long-term reduction in colorectal cancer incidence and mortality.

10 Nov, 2021 | 07:04h | UTC

Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial – Annals of Internal Medicine

Commentaries:

Flexible sigmoidoscopy associated with long-term reduction in colorectal cancer incidence, mortality – ACP Internist

Flexible sigmoidoscopy screening associated with long-term reduction in colorectal cancer incidence and mortality – American College of Physicians

Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.

10 Nov, 2021 | 06:57h | UTC

Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary: Choosing between antipsychotics to reduce the risk of breast cancer in women with schizophrenia – The Mental Elf

Commentary on Twitter

Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051

— P𝘧OL (@psychopharmacol) September 12, 2021

Cohort study: In utero exposure to 17α-hydroxyprogesterone caproate linked to increased risk of cancer in offspring.

10 Nov, 2021 | 06:59h | UTC

In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring – American Journal of Obstetrics and Gynecology (link to abstract – $ for full-text)

Commentary: Drug used to prevent miscarriage increases risk of cancer in offspring – The University of Texas Health Science Center at Houston

Practice Review: COVID-19 rapid diagnostics.

9 Nov, 2021 | 01:52h | UTC

COVID-19 rapid diagnostics: practice review – Emergency Medicine Journal

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

9 Nov, 2021 | 01:46h | UTC

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic – JAMA Internal Medicine

Author Interview: Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Results With Persistent Physical Symptoms – JAMA Internal Medicine

Commentaries: Expert reaction to study looking at the association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms – Science Media Centre

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Commentary on Twitter

Except for anosmia, persistent symptoms after COVID-19 may be more related to the belief of having had #COVID19 than to actual SARS-Co-V2 infection. Clinicians and researchers should also consider general mechanisms that may not be specific to #SARSCoV2 https://t.co/IdSh5GhdQ6

— JAMA Internal Medicine (@JAMAInternalMed) November 8, 2021

Choosing Wisely: Nine pediatric otolaryngology recommendations.

9 Nov, 2021 | 01:09h | UTC

Choosing Wisely Canada – pediatric otolaryngology recommendations – Journal of Otolaryngology – Head & Neck Surgery

See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.

9 Nov, 2021 | 01:17h | UTC

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

Choosing Wisely for Thyroid Conditions: Ten things clinicians and patients should question – “Do not order thyroid ultrasound for nodule detection in patients without thyroid anatomic anomalies on clinical examination”.

9 Nov, 2021 | 01:11h | UTC

Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

7 Nov, 2021 | 20:35h | UTC

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Commentaries:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

Commentary on Twitter (thread – click for more)

Pfizer’s oral protease inhibitor PF-07321332 for #COVID19 Reduced Risk of Hospitalization or Death from 6.7% (41/612) to 1.0% (6/607) when starting within 5 days of symptom onset.
10 vs 0 deaths. #idtwitter https://t.co/ZAIm6Y5mAt

— David Boulware, MD MPH (@boulware_dr) November 5, 2021

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.

7 Nov, 2021 | 20:29h | UTC

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination – Clinical Infectious Diseases

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Viewpoint | Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.

7 Nov, 2021 | 20:31h | UTC

Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA

Viewpoint | Children and COVID-19 in schools.

7 Nov, 2021 | 20:24h | UTC

Children and COVID-19 in schools – Science

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

CDC Report: Schools without mask requirements were more likely to have Covid-19 outbreaks.

Perspective | Schools have begun mass testing for COVID-19. But hurdles and uncertainties remain.

COVID and schools: the evidence for reopening safely.

COVID studies note online learning stress, fewer cases in schools with protocols

[Not published yet] Chinese drug firm Sinovac says Covid-19 vaccine safe for children and babies as young as six months old.

7 Nov, 2021 | 20:32h | UTC

Chinese drug firm Sinovac says Covid-19 vaccine safe for children, babies as young as six months old; submits data to Hong Kong government – South China Morning Post

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.

7 Nov, 2021 | 20:27h | UTC

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety – Drug Safety

RCT: In patients with advanced chronic kidney disease and poorly controlled hypertension, Chlortalidone had a significant impact in blood-pressure control (−11.0 mm Hg vs. −0.5 mm Hg in the placebo group).

7 Nov, 2021 | 20:20h | UTC

Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cheap Diuretic, Chlorthalidone, Drops BP in Advanced Kidney Disease – Medscape (free registration required)

Commentary on Twitter

In this placebo-controlled trial involving patients with advanced chronic kidney disease and poorly controlled hypertension, chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with placebo. #KidneyWk https://t.co/iNZc2mYy2c pic.twitter.com/7svX4RVtPI

— NEJM (@NEJM) November 5, 2021

NICE draft guideline recommends SGLT2 inhibitor dapagliflozin for some patients with chronic kidney disease.

7 Nov, 2021 | 20:14h | UTC

NICE recommend dapagliflozin for people with chronic kidney disease – National Institute for Health and Care Excellence

See draft guideline:

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version)

NICE Guideline: Assessment and management of chronic kidney disease.

Secondary analysis of RCT finds Dapagliflozin is safe for patients with stage 4 chronic kidney disease.

Randomized trial: Dapagliflozin in patients with chronic kidney disease

Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

5 Nov, 2021 | 09:59h | UTC

Original study: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 – Science

News release: Breakthrough Infection Study Compares Decline in Vaccine Effectiveness and Consequences for Mortality – Public Health Institute

Commentary on Twitter

A new study of more than 780,000 United States Veterans shows that, although vaccination remains protective against #SARSCoV2 infection, protection waned as the Delta variant emerged in America.

Read more: https://t.co/8qRlKE107H #ScienceResearch pic.twitter.com/XmDQ7frIlT

— Science Magazine (@ScienceMagazine) November 4, 2021

Review: SARS-CoV-2 indoor air transmission is a threat that can be addressed with science.

5 Nov, 2021 | 09:55h | UTC

SARS-CoV-2 indoor air transmission is a threat that can be addressed with science – Proceedings of the National Academies of Sciences

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

Editorial: Covid-19 has redefined airborne transmission

Covid-19: What do we know about airborne transmission of SARS-CoV-2?

Real-world data show that filters clean COVID-causing virus from air.

Perspective | The plan to stop every respiratory virus at once – “The benefits of ventilation reach far beyond the coronavirus. What if we stop taking colds and flus for granted, too?”

Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission.

We studied how to reduce airborne COVID spread in hospitals. Here’s what we learnt.

Report: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers.

WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk

Guidance: Using Ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes

It’s not just SARS-CoV-2: Most respiratory viruses spread by aerosols.

Commentary on Twitter

Addressing #CovidisAirborne with sciencehttps://t.co/puzxHQ6xGD
proceedings of a workshop with the experts @PNASNews w/ @Smogdr @linseymarr @kprather88 @Lakdawala_Lab @Prof_Lowe pic.twitter.com/xdjjFZ8Uto

— Eric Topol (@EricTopol) November 5, 2021